A Multicenter, Phase II Trial of Schedule Modification for Nab-Paclitaxel in Combination with Ramucirumab for Patients with Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer: The B-RAX Trial (JACCRO GC-09)

Kawabata, Ryohei; Izawa, Naoki; Suzuki, Takahisa; Nagahisa, Yoshio; Nishikawa, Kazuhiro; Takahashi, Mutsuo; Nakamura, Masato; Ishiguro, Atsushi; Katsuya, Hiroo; Hihara, Jun; Manaka, Dai; Negoro, Yuji; Tsuji, Akihito; Takahashi, Tsuyoshi; Kochi, Mitsugu; Azuma, Mizutomo; Kadowaki, Shigenori; Michimae, Hirofumi; Sunakawa, Yu; Ichikawa, Wataru; Fujii, Masashi

doi:10.1007/s11523-023-00961-x

Targ Oncol

2023

DOI: 10.1007/s11523-023-00961-x

|View full text |Cite

A Multicenter, Phase II Trial of Schedule Modification for Nab-Paclitaxel in Combination with Ramucirumab for Patients with Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer: The B-RAX Trial (JACCRO GC-09)

Ryohei Kawabata

Naoki Izawa

Takahisa Suzuki

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article3

Relationship

Self Cite0

Independent3

Authors

Journals

Cited by 3 publications

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Targeting esophageal carcinoma: molecular mechanisms and clinical studies

Wang,

Ye,

et al. 2024

MedComm

View full text Add to dashboard Cite

Esophageal cancer (EC) is identified as a predominant health threat worldwide, with its highest incidence and mortality rates reported in China. The complex molecular mechanisms underlying EC, coupled with the differential incidence of esophageal squamous cell carcinoma (ESCC) and esophageal adenocarcinoma (EAC) across various regions, highlight the necessity for in‐depth research targeting molecular pathogenesis and innovative treatment strategies. Despite recent progress in targeted therapy and immunotherapy, challenges such as drug resistance and the lack of effective biomarkers for patient selection persist, impeding the optimization of therapeutic outcomes. Our review delves into the molecular pathology of EC, emphasizing genetic and epigenetic alterations, aberrant signaling pathways, tumor microenvironment factors, and the mechanisms of metastasis and immune evasion. We further scrutinize the current landscape of targeted therapies, including the roles of EGFR, HER2, and VEGFR, alongside the transformative impact of ICIs. The discussion extends to evaluating combination therapies, spotlighting the synergy between targeted and immune‐mediated treatments, and introduces the burgeoning domain of antibody–drug conjugates, bispecific antibodies, and multitarget‐directed ligands. This review lies in its holistic synthesis of EC's molecular underpinnings and therapeutic interventions, fused with an outlook on future directions including overcoming resistance mechanisms, biomarker discovery, and the potential of novel drug formulations.

show abstract

Targeting esophageal carcinoma: molecular mechanisms and clinical studies

Wang,

Ye,

et al. 2024

MedComm

View full text Add to dashboard Cite

show abstract

Construction and validation of the prognostic nomogram model for patients with diffuse-type gastric cancer based on the SEER database

Huang,

Chan,

Zhou

et al. 2024

Discov Onc

View full text Add to dashboard Cite

Objective The prognostic factors of diffuse GC patients were screened the prognostic nomogram was constructed, and the prediction accuracy was verified. Methods From 2006 to 2018, there were 2877 individuals pathologically diagnosed with diffuse gastric cancer; the clinicopathological features of these patients were obtained from the SEER database & randomly divided into a training cohort (1439) & validation cohort (1438).To create prognostic nomograms & choose independent prognostic indicators to predict the overall survival (OS) of 1, 3, & 5 years, log-rank & multivariate COX analysis were utilized & discrimination ability of nomogram prediction using consistency index and calibration curve. Results Age, T, N, M, TNM, surgical status, chemotherapy status, & all seven markers were independent predictors of OS (P < 0.05), & a nomogram of OS at 1, 3, & 5 years was created using these independent predictors. The nomogram's c-index was 0.750 (95% CI 0.734 ~ 0.766), greater than the TNM staging framework 0.658 (95%CI 0.639 ~ 0.677); the c-index was 0.753 (95% CI 0.737 ~ 0.769) as well as superior to the TNM staging mechanism 0.679 (95% CI 0.503–0.697). According to the calibration curve, the projected survival rate using the nomogram & the actual survival rate are in good agreement. Conclusions Prognostic nomograms are useful tools for physicians to assess every individual's individualised prognosis & create treatment strategies for those with diffuse gastric cancer. They can reliably predict the prognosis for individuals with diffuse gastrointestinal carcinoma.

show abstract

Design, synthesis and biological evaluation of plant-derived miliusol derivatives achieve TNBC profound regression in vivo

Zhao,

Cheng,

Liu

et al. 2024

European Journal of Medicinal Chemistry

View full text Add to dashboard Cite

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

A Multicenter, Phase II Trial of Schedule Modification for Nab-Paclitaxel in Combination with Ramucirumab for Patients with Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer: The B-RAX Trial (JACCRO GC-09)

Cited by 3 publications

References 17 publications

Targeting esophageal carcinoma: molecular mechanisms and clinical studies

Targeting esophageal carcinoma: molecular mechanisms and clinical studies

Construction and validation of the prognostic nomogram model for patients with diffuse-type gastric cancer based on the SEER database

Design, synthesis and biological evaluation of plant-derived miliusol derivatives achieve TNBC profound regression in vivo

Contact Info

Product

Resources

About